Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameTranscenta-B
Stock Code06628
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家集發現、研究、開發、製造及業務拓展能力為一體的臨床階段生物製藥公司,專注腫瘤、腎病及骨骼疾病等領域的抗體管線。
Listing Date2021-09-29
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國蘇州星湖街218號生物納米園B6-501室,郵政編碼215123
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.transcenta.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 16.00 / shares
Offer Price RangeFinal offer price only, no range
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2021-09-14 to 2021-09-17
Global Offering Shares40,330,000 shares
HK Public Offer Shares (Initial)4,033,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)36,297,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO445,331,917 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share69.6%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 645,280,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 670.4M
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +1346%

Valuation & Financials

Market Cap (at Offer Price)HK$ 7,125,310,672
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損約人民幣322.9百萬元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 70,647,000
Listing Expenses / Funds Raised~10.95%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Revenue 44,14080,980
Cost of sales -37,226-62,778
Gross profit 6,91418,202
Other income and gains, net -85,54538,689
Selling and distribution expenses -1,302-2,759
Administrative expenses -121,616-155,190
Net finance costs -10,408-16,070
Share of associates and JVs 00
Profit before tax -426,520-323,010
Income tax expense -10,834110
Profit for the year -437,354-322,900
Profit attributable to owners -395,256-316,626
Balance Sheet
Item 201920202021
Cash and cash equivalents 458,100813,5921,038,373
Trade and bills receivables 18,72131,63533,476
Inventories 6,3157,90111,746
Total current assets 487,945891,4571,138,317
Total assets 1,565,7152,090,9242,345,754
Total current liabilities 149,979194,537211,287
Total liabilities 2,201,8752,907,1693,228,576
Total equity -636,160-816,245-882,822
Equity attributable to owners -836,967-816,245-882,822
Cash Flow Statement
Item 201920202021-03
Net cash from operating activities -234,960-174,398
Net cash from investing activities -232,280-57,738
Net cash from financing activities 551,210967,401
Net increase in cash 83,970735,265
Depreciation of PP&E 34,04033,3827,806
Depreciation of right-of-use assets 5,9998,1401,329
Amortisation of intangible assets 601606116
Purchase of PP&E -154,735-63,329-12,720
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 13.24
First Day OpenHK$ 13.0
First Day Change-17.25%
First Day Volume11079000.0
First Day Turnover143255000.0
Use of Proceeds
1、82%或約471.0百萬港元用于我們管線候選產品的研發、為進行中及計劃中的臨床及臨床前試驗、籌備注冊備案以及其他與商業化我們四款主打產品有關的步驟或活動撥資; 2、8%或約46.0百萬港元用于為擴充管線及開發技術的業務發展撥資; 3、10%或約57.4百萬港元用作一般營運資金及一般營運費用。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 中银国际亚洲有限公司 CE AET863 China Renaissance Securities (Hong Kong) Limited CE AZX839
Joint Bookrunners (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 中银国际亚洲有限公司 CE AET863 China Renaissance Securities (Hong Kong) Limited CE AZX839
Joint Lead Managers (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 中银国际亚洲有限公司 CE AET863 China Renaissance Securities (Hong Kong) Limited CE AZX839

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Aranda Investments Pte. Ltd. 33,032,000 HKD — 5.12% — 6 months 2022-03-29
2 LAV Amber Limited 52,856,000 HKD — 8.19% — 6 months 2022-03-29
3 QH Oil Investments LLC 165,200,000 HKD — 25.60% — 6 months 2022-03-29
4 中国国有企业结构调整基金股份有限公司 198,240,000 HKD — 30.72% — 6 months 2022-03-29

Directors & Management

PositionChinese nameEnglish Name
Chairman趙奕寧—
Company Secretary朱達、梁君慧—
No director data available.

Major Shareholders

Major Shareholders & Holdings錢雪明博士(約12.84%)、HSBC Trust Company (Delaware) National Association(約10.25%)、Yi Shi(透過LAV集團,約15.10%)
About this page

This page shows Transcenta-B (06628) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect